glp 1 asa guidelines Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists Glucagon-Like Peptide-1 Receptor Agonists–Health Professional

The introduction of new GLP-1 receptor agonists, a robust product pipeline for diabetes and obesity treatments, together with the high efficacy of these medications, is expected to drive market growth [67]

doi: 10.1210/jc.2010-2318

2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology Solution set oversight committee

A treatment-related increase in benign thyroid C-cell adenomas was seen in males in 0.25 and 0.75 mg/kg/day liraglutide groups with incidences of 12%, 16%, 42%, and 46% and in all female liraglutide-treated groups with incidences of 10%, 27%, 33%, and 56% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively

Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, Egan JM: Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes

Special tubes that stop DPP-4 are used for this